Episode 252: Talazoparib and Its FDA Approval in CRPC

Neeraj Agarwal, MD, joins us to discuss the TALAPRO-2 study and the relevance of homologous recombination repair biomarkers in the study’s 2 cohorts. We also discuss other PARP inhibitors and BRCA 1/2 occurrences.
Dr. Agarwal is a professor of medicine and a Presidential Endowed Chair of Cancer Research at the Huntsman Cancer Institute, University of Utah. He is also director of the institute’s Genitourinary Oncology Program, and the Center of Investigational Therapeutics.